The U.S. Food and Drug Administration (FDA) has expanded its approval of Vonvendi (recombinant von Willebrand factor), a treatment for von Willebrand disease (VWD).
News
Using both corticosteroids and plasma exchange therapy — each a standard treatment for acquired thrombotic thrombocytopenic purpura (TTP) — together was found to significantly…
A man in his 60s with immune thrombocytopenia (ITP) experienced repeated strokes even while taking anticoagulant medications — commonly known as blood thinners —…
The severity of bleeding in type 2 von Willebrand disease (VWD) can vary widely between subtypes and even among patients who carry the same…
The congenital form of thrombotic thrombocytopenic purpura (TTP) can look very different in one person than in another, but preventive treatment can help reduce…
Patients, caregivers, medical professionals, and other advocates are coming together in September for Immune Thrombocytopenia Awareness Month to raise awareness and support for a…
Children with von Willebrand disease (VWD) have reduced health-related quality of life, although the specific areas that seem to be most affected depend on…
Note: This story was updated Sept. 2, 2025, to clarify the definition of a durable platelet response used in LUNA 3. The U.S. Food and…
A woman in Spain delivered a full-term, healthy baby after she was identified early as having congenital thrombotic thrombocytopenic purpura (TTP) and treated successfully…
Daratumumab, an injection therapy approved to treat myeloma, may help to control immune thrombocytopenia (ITP) in individuals whose disease doesn’t respond well to available…
